Physician profile
Peer A Soderberg
NPI 1316926397
$6,813.25
in general payments reported to CMS, 2019-2025
45 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $645 · 2021: $863 · 2022: $741 · 2023: $757 · 2024: $1,676 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $920.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $874.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $777.95 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $394.85 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $387.94 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Pfizer INC. | $334.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $307.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $294.29 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.88 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $219.92 | 2021-2025 | Trintellix |
| Amgen INC. | $219.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.02 | 2019-2024 | Xifaxan |
| Antares Pharma, INC. | $111.79 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Bausch Health US, LLC | $110.34 | 2022-2024 | Aplenzin, Wellbutrin |
| Amarin Pharma, INC. | $102.26 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peer Soderberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.